Literature DB >> 18197467

Extensions to the visual predictive check to facilitate model performance evaluation.

Teun M Post1, Jan I Freijer, Bart A Ploeger, Meindert Danhof.   

Abstract

The Visual Predictive Check (VPC) is a valuable and supportive instrument for evaluating model performance. However in its most commonly applied form, the method largely depends on a subjective comparison of the distribution of the simulated data with the observed data, without explicitly quantifying and relating the information in both. In recent adaptations to the VPC this drawback is taken into consideration by presenting the observed and predicted data as percentiles. In addition, in some of these adaptations the uncertainty in the predictions is represented visually. However, it is not assessed whether the expected random distribution of the observations around the predicted median trend is realised in relation to the number of observations. Moreover the influence of and the information residing in missing data at each time point is not taken into consideration. Therefore, in this investigation the VPC is extended with two methods to support a less subjective and thereby more adequate evaluation of model performance: (i) the Quantified Visual Predictive Check (QVPC) and (ii) the Bootstrap Visual Predictive Check (BVPC). The QVPC presents the distribution of the observations as a percentage, thus regardless the density of the data, above and below the predicted median at each time point, while also visualising the percentage of unavailable data. The BVPC weighs the predicted median against the 5th, 50th and 95th percentiles resulting from a bootstrap of the observed data median at each time point, while accounting for the number and the theoretical position of unavailable data. The proposed extensions to the VPC are illustrated by a pharmacokinetic simulation example and applied to a pharmacodynamic disease progression example.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197467      PMCID: PMC2798054          DOI: 10.1007/s10928-007-9081-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  18 in total

1.  Multiple imputation for model checking: completed-data plots with missing and latent data.

Authors:  Andrew Gelman; Iven Van Mechelen; Geert Verbeke; Daniel F Heitjan; Michel Meulders
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

2.  Prediction discrepancies for the evaluation of nonlinear mixed-effects models.

Authors:  France Mentré; Sylvie Escolano
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-13       Impact factor: 2.745

3.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

4.  Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

Authors:  V A Bhattaram; C Bonapace; D M Chilukuri; J Z Duan; C Garnett; J V S Gobburu; S H Jang; L Kenna; L J Lesko; R Madabushi; Y Men; J R Powell; W Qiu; R P Ramchandani; C W Tornoe; Y Wang; J J Zheng
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

Review 5.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Authors:  Nicholas H G Holford; Phylinda L S Chan; John G Nutt; Karl Kieburtz; Ira Shoulson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-20       Impact factor: 2.745

Review 7.  Model-based drug development.

Authors:  R L Lalonde; K G Kowalski; M M Hutmacher; W Ewy; D J Nichols; P A Milligan; B W Corrigan; P A Lockwood; S A Marshall; L J Benincosa; T G Tensfeldt; K Parivar; M Amantea; P Glue; H Koide; R Miller
Journal:  Clin Pharmacol Ther       Date:  2007-05-23       Impact factor: 6.875

8.  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Authors:  Willem de Winter; Joost DeJongh; Teun Post; Bart Ploeger; Richard Urquhart; Ian Moules; David Eckland; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-22       Impact factor: 2.745

9.  Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients.

Authors:  Lanyan Fang; Nicholas H G Holford; George Hinkle; Xianhua Cao; Jim J Xiao; Mark Bloomston; Seth Gibbs; Osama Habib Al Saif; James T Dalton; Kenneth K Chan; Jeffery Schlom; Edward W Martin; Duxin Sun
Journal:  J Clin Pharmacol       Date:  2007-02       Impact factor: 3.126

10.  Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.

Authors:  Meng H Tan; Arun Baksi; Boris Krahulec; Piotr Kubalski; Andrzej Stankiewicz; Richard Urquhart; Gareth Edwards; Don Johns
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

View more
  71 in total

1.  Automatic data binning for improved visual diagnosis of pharmacometric models.

Authors:  Marc Lavielle; Kevin Bleakley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-26       Impact factor: 2.745

2.  Visual Predictive Check in Models with Time-Varying Input Function.

Authors:  Anna Largajolli; Alessandra Bertoldo; Marco Campioni; Claudio Cobelli
Journal:  AAPS J       Date:  2015-08-12       Impact factor: 4.009

3.  Pharmacokinetics of ε-Aminocaproic Acid in Neonates Undergoing Cardiac Surgery with Cardiopulmonary Bypass.

Authors:  Michael P Eaton; George M Alfieris; Dawn M Sweeney; Ronald E Angona; Jill M Cholette; Charles Venuto; Brian Anderson
Journal:  Anesthesiology       Date:  2015-05       Impact factor: 7.892

4.  Evaluation of different tests based on observations for external model evaluation of population analyses.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-23       Impact factor: 2.745

5.  A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

Authors:  Thorsten Lehr; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Hans-Guenter Schaefer; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Population pharmacokinetic analysis of varenicline in adult smokers.

Authors:  Patanjali Ravva; Marc R Gastonguay; Thomas G Tensfeldt; Hélène M Faessel
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

7.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

8.  Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Authors:  Martin Bergstrand; Andrew C Hooker; Johan E Wallin; Mats O Karlsson
Journal:  AAPS J       Date:  2011-02-08       Impact factor: 4.009

9.  A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.

Authors:  Sami Ullah; Peter Matzneller; Markus Zeitlinger; Uwe Fuhr; Max Taubert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-06       Impact factor: 3.000

10.  Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.

Authors:  Thorsten Lehr; Alexander Staab; Dirk Trommeshauser; Hans Guenter Schaefer; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.